compound 20 [Bergeron et al., 2016]   Click here for help

GtoPdb Ligand ID: 9171

PDB Ligand
Compound class: Synthetic organic
Comment: Compound 20 is a type II inhibitor (binds in a DMG-out mode) of CDK8, with an improved selectivity profile compared to sorafenib [2]. It is one of the compounds claimed in patent WO2015049325 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 94.65
Molecular weight 479.23
XLogP 2.33
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CNc1nccc(n1)N1CCC(C1)NC(=O)Nc1ccc(c(c1)C(F)(F)F)CN1CCOCC1
Isomeric SMILES CNc1nccc(n1)N1CC[C@@H](C1)NC(=O)Nc1ccc(c(c1)C(F)(F)F)CN1CCOCC1
InChI InChI=1S/C22H28F3N7O2/c1-26-20-27-6-4-19(30-20)32-7-5-17(14-32)29-21(33)28-16-3-2-15(18(12-16)22(23,24)25)13-31-8-10-34-11-9-31/h2-4,6,12,17H,5,7-11,13-14H2,1H3,(H,26,27,30)(H2,28,29,33)/t17-/m0/s1
1. Bergeron P, Koehler M. (2015)
Therapeutic inhibitors of cdk8 and uses thereof.
Patent number: WO2015049325. Assignee: F. Hoffmann-La Roche Ag, Genentech, Inc.. Priority date: 03/10/2013. Publication date: 09/04/2015.
2. Bergeron P, Koehler MF, Blackwood EM, Bowman K, Clark K, Firestein R, Kiefer JR, Maskos K, McCleland ML, Orren L et al.. (2016)
Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.
ACS Med Chem Lett, 7 (6): 595-600. [PMID:27326333]
3. Dale T, Clarke PA, Esdar C, Waalboer D, Adeniji-Popoola O, Ortiz-Ruiz MJ, Mallinger A, Samant RS, Czodrowski P, Musil D et al.. (2015)
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
Nat Chem Biol, 11 (12): 973-80. [PMID:26502155]